currently enrolling
flying towards new horizons
working to elevate human health
At Terns, we're a passionate team of experts who wake up every day thinking about how to make your life better - whether you or a loved one are living with cancer, obesity, or other serious health issues. We're dedicated to accelerating the discovery and development of medicines. Our nimble, caring approach builds upon clinically proven foundations in an effort to create better therapies that not only treat disease but also transform lives. Because you deserve medicines that work better, have fewer side effects, are more convenient, and offer genuine hope for the challenges you face today and the possibilities you envision for tomorrow. We're not just developing medicines; we're building hope - one innovation at a time.
clinical trials
Terns is focused on discovering, researching, and developing potential medicines with the hope that people with serious diseases can lead better lives. Our thoughtful approach to clinical trial design enables us to move quickly and efficiently while prioritizing the safety of participants.
We are grateful to our clinical trial participants, as well as their families. You are making a positive contribution towards a better future for all people living with severe diseases.
FULLY ENROLLED
For more information about these trials, email [email protected]. If you’re interested in participating in a Terns trial, we encourage you to speak with your doctor about what might be involved and your eligibility.
CURRENTLY ENROLLING
CARDINAL: An open-label Phase 1 study of TERN-701 in people with previously treated CML
CARDINAL (trial registration number NCT06163430) is looking at the safety, tolerability, and efficacy (how well it works) of a once-daily oral investigational medication called TERN-701 in people with CML who have been previously treated with one or more tyrosine kinase inhibitors (TKIs) and who stopped responding, did not respond, or could not tolerate these treatments.
Who can participate?
- Men or women over 18 years of age with a confirmed diagnosis of BCR::ABL1-positive CML in chronic phase (note that your CML must NOT be in accelerated or blast phase)
- Previously treated with one or more TKIs
- If you had side effects with a previous anti-cancer therapy, the side effects must be resolved before you can participate in CARDINAL
Other criteria apply; the research study staff will determine if you qualify to enroll in CARDINAL.
FULLY ENROLLED
FALCON: A Phase 2 study of TERN-601 in obese or overweight adults
FALCON (trial registration number NCT06854952) is looking at the safety, tolerability, and efficacy (how well it works) of a once-daily oral investigational medication called TERN-601 vs placebo in people who are overweight or obese. The aim is to measure the body’s response to TERN-601 or placebo, including any changes in body weight and how well the study medicine is tolerated.
Who can participate?
- Men or women 18–75 years of age diagnosed with obesity or who are overweight with at least one of the following: Abnormal lipids, high blood pressure, sleep apnea
- Must NOT have diabetes
- Must NOT have had surgery or a device-based therapy for obesity
Other criteria apply; the research study staff will determine if you qualify to enroll in FALCON.
This clinical trials page is a resource designed to support, inform, and help patients and their relatives or caregivers in a clinical study or those who are interested in participating. The information on this page is intended for informational purposes only and should not be used as a substitute for seeking medical advice or treatment from a healthcare professional. You should not use this information to diagnose or treat a medical condition or health problem. Speak to a healthcare professional if you have any questions about your health, medical condition, symptoms, or treatment options.
resources
The resources listed below are provided as a starting point to help people with CML or obesity access information about - and resources related to - their condition.
CML
Obesity
Terns Pharmaceuticals is providing these links as helpful resources for patients and caregivers. Inclusion on this list above does not represent an endorsement or a recommendation from Terns for any group or organization. The organizations listed are independent of Terns Pharmaceuticals.